BioSpace News Archive

Today at ACP’s annual meeting, Internal Medicine Meeting 2024, Annals of Internal Medicine presented three breaking scientific research articles during a live scientific plenary session that featured the authors of those articles.

Pieris Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024.

The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes.

Mednet, a healthcare technology company, today announced Senior Project Manager Stacey Lasser will present at the 2nd Annual Clinical Outsourcing Group (COG) New England conference in Boston, Massachusetts from April 23 – 24, 2024.

The global DNA diagnostics market size was estimated at USD 10.69 billion in 2023 and is projected to hit around USD 16.05 billion by 2033, growing at a CAGR of 4.15% during the forecast period from 2024 to 2033 according to a new report by Nova One Advisor.

The global pharmaceutical CDMO market size was accounted for USD 146.29 billion in 2023 and it is increasing around USD 295.95 billion by 2033 with a CAGR of 7.3% from 2024 to 2033. according to a new report by Nova One Advisor.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company.

Sermonix Pharmaceuticals Inc. today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m. ET, featuring Senthil Damodaran, M.D., Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D. (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Grifols, S.A., a global healthcare company and leading manufacturer of plasma-derived medicines, announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission.